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Azithromycin attenuates airway inflammation in a
mouse model of viral bronchiolitis
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Avraham Beigelman*1, Cassandra L Mikols2, Sean P Gunsten2, Carolyn L Cannon1, Steven L Brody2 and
Michael J Walter2

Abstract
Background: Viral bronchiolitis is the leading cause of hospitalization in young infants. It is associated with the
development of childhood asthma and contributes to morbidity and mortality in the elderly. Currently no therapies
effectively attenuate inflammation during the acute viral infection, or prevent the risk of post-viral asthma. We
hypothesized that early treatment of a paramyxoviral bronchiolitis with azithromycin would attenuate acute and
chronic airway inflammation.
Methods: Mice were inoculated with parainfluenza type 1, Sendai Virus (SeV), and treated daily with PBS or
azithromycin for 7 days post-inoculation. On day 8 and 21 we assessed airway inflammation in lung tissue, and
quantified immune cells and inflammatory mediators in bronchoalveolar lavage (BAL).
Results: Compared to treatment with PBS, azithromycin significantly attenuated post-viral weight loss. During the peak
of acute inflammation (day 8), azithromycin decreased total leukocyte accumulation in the lung tissue and BAL, with
the largest fold-reduction in BAL neutrophils. This decreased inflammation was independent of changes in viral load.
Azithromycin significantly attenuated the concentration of BAL inflammatory mediators and enhanced resolution of
chronic airway inflammation evident by decreased BAL inflammatory mediators on day 21.
Conclusions: In this mouse model of paramyxoviral bronchiolitis, azithromycin attenuated acute and chronic airway
inflammation. These findings demonstrate anti-inflammatory effects of azithromycin that are not related to anti-viral
activity. Our findings support the rationale for future prospective randomized clinical trials that will evaluate the effects
of macrolides on acute viral bronchiolitis and their long-term consequences.
Background
Viral bronchiolitis is the most common acute infection of
the lower respiratory tract in infancy, and is most often
caused by the paramyxoviruses, especially respiratory
syncytial virus (RSV). RSV will infect 95% of children by
the age of 2 [1], and up to 3% of infected children will
develop a severe bronchiolitis requiring hospitalization
[2]. The rate of admissions has doubled in the past 2
decades [3]; as a result, severe RSV bronchiolitis is now
the leading cause of hospitalization in infants younger the
age of 1 year [4]. Chronic respiratory symptoms are common after severe RSV bronchiolitis, with about 40% of
hospitalized children eventually developing asthma [5-8].
The development of asthma following RSV infection
* Correspondence: beigelman_a@kids.wustl.edu
1

Division of Allergy, Immunology & Pulmonary Medicine, Department of
Pediatrics, Washington University School of Medicine, St. Louis, MO; USA

appears to be related to the severity of the initial infection
[9]. RSV infection is not limited to children and contributes significantly to morbidity and mortality in the elderly
population [10]. These findings suggest that attenuating
the acute viral infection may be an effective strategy to
attenuate the acute and long-term consequences of viral
bronchiolitis.
No specific therapies are currently recommended for
severe RSV bronchiolitis [11]. Ideally a beneficial pharmacologic agent would reduce acute morbidity as well as
modify the anti-viral host response to avert the subsequent development of asthma. One class of potentially
useful therapeutic agents is the macrolide antibiotics,
since they possess distinct anti-inflammatory properties
in addition to their antimicrobial effects [12-25]. Two
clinical studies have evaluated macrolide treatment during severe RSV bronchiolitis in children, but these studies
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have yielded conflicting results [26,27]. Therefore, definitive conclusions regarding the usefulness of macrolides as
a treatment of viral-bronchiolitis cannot be made at this
time.
To examine the anti-inflammatory properties of macrolides in a high fidelity animal model of human RSV
bronchiolitis, we tested the ability of azithromycin to
modulate a well-characterized viral bronchiolitis model
using a mouse parainfluenza type I virus, referred to as
Sendai virus (SeV) [28,29]. SeV replicates at high efficiency in the mouse lung and results in an acute viral
bronchiolitis, and chronic airway inflammation that persists for at least one year following viral inoculation
[28,29]. We hypothesized that treatment of mouse SeV
bronchiolitis with azithromycin during the acute infection would attenuate early airway inflammation, and also
decrease the chronic post-viral pathologic abnormalities,
such as immune cell accumulation and the mediators that
drive these processes.

Materials and methods
Mice

C57BL/6J female mice were purchased from the Jackson
Laboratory (Bar Harbor, ME). All mice were bred and
housed under specific pathogen-free conditions at Washington University School of Medicine where sentinel
mice (pathogen free ICN-strain) exhibited no serologic or
histologic evidence of exposure to 15 murine pathogens
(including SeV). Before performing these in vivo experiments, we investigated whether our colony of mice were
actively infected or colonized with bacteria in the trachea
and lungs. We obtained tracheal swabs and tissue samples from both lungs, from 5 mice, and plated them on
tryptic soy agar plates supplemented with 5% sheep
blood, incubated for 48 hours at 37°C and no colonies
were identified. To determine if our colony of mice had
serologic evidence of prior Mycoplasma pulmonis exposure, serum was collected for indirect ELISA using Mycoplasma pulmonis antigen-coated plates according to
manufacturer's recommendations (Charles River Laboratories, Wilmington, MA). These results were negative for
infection as previously included in our prior manuscript
[30]. In addition, we have tested our SeV stock for bacterial contamination by streaking the viral stock on tryptic
soy agar plates supplemented with 5% sheep blood followed by incubated for 48 hours at 37°C. No colonies
were identified. The Institutional Animal Use and Care
Committee of Washington University School of Medicine
approved all animal experiments.
Induction of viral bronchiolitis

SeV, a mouse parainfluenza type 1 virus that is similar to
the human paramyxoviruses (a class of viruses that
includes RSV, metapneumovirus, and parainfluenza
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viruses) was used to generate airway inflammation of the
small airways (i.e., viral bronchiolitis) as we previously
described [29,31,32]. On day zero, seven-week-old
C57BL/6J female mice underwent anesthesia and intranasal inoculation with SeV (Fushimi Strain, ATCC #VR105) at 5,000 egg infectious dose 50% (5 K). This dose
generates a sub-lethal tracheobronchitis/bronchiolitis
viral infection [31,32]. On days 8 and 21 post-inoculation,
the mice were anesthetized and euthanized for bronchoalveolar lavage (BAL) fluid and lung tissue collection as
we previously described (see experiment design, Figure
1A) [29-33]. The day 8 time point corresponds to the
peak of acute airway inflammation, while the day 21 time
point corresponds to a chronic inflammatory phase of the
infection [29,31]. Each experiment was repeated 3 times
with multiple animals in each treatment group.
Azithromycin treatment

Mice were treated daily with subcutaneous azithromycin
(50 mg/kg dissolved in 100 μL sterile PBS, purchased
from Pfizer Pharmaceuticals, Dublin, Ireland), from day 0
(one hour after SeV inoculation) through day 7 post-viral
inoculation. Mice that were treated with subcutaneous
100 μL sterile PBS served as a control for the azithromycin treatment. Azithromycin dose was determined based
on our previous pharmacokinetic studies [30] which
demonstrated that daily subcutaneous treatment of mice
with azithromycin (50 mg/kg) produced serum levels
similar to those observed in humans treated with the recommended azithromycin dose. Overall, a higher dosage
of azithromycin is required in mice than humans due to
more rapid liver metabolism in mice, resulting in an elimination half-life of 2.3 hours compared to 68 hours in
humans [34,35].
Mouse specimen analyses

BAL and lung tissue harvest were performed as previously described [29-32]. Two blinded observers determined the BAL immune cell differential using standard
light microscopy criteria as described previously [30,31].
BAL inflammatory mediators were analyzed using a multiplex flow-cytometry based assay according to manufacturer's recommendations (Bio-Rad Laboratories) and as
previously described [30,31]. The detection limit for the
Bio-plex mouse cytokine 23-plex panel (Bio-Rad) is: IL1α - 2 pg/ml; IL-1β - 2 pg/ml; IL-2 - 3 pg/ml; IL-3 - 2 pg/
ml; IL-4 - 3 pg/ml; IL-5 - 2 pg/ml; IL-6 - 2 pg/ml; IL-9 - 15
pg/ml; IL-10 - 2 pg/ml; IL-12 (p40) - 2 pg/ml; IL-12 (p70)
- 4 pg/ml; IL-13 - 9 pg/ml; IL-17 - 1 pg/ml; eotaxin - 148
pg/ml; G-CSF - 1 pg/ml; GM-CSF - 7 pg/ml; IFN-γ - 6 pg/
ml; KC - 3 pg/ml; CCL2/JE - 14 pg/ml; CCL3/MIP-1β - 24
pg/ml; CCL4/MIP-1ί - 2 pg/ml; CCL5/RANTES - 5 pg/
ml; and TNF-α - 6 pg/ml.
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Figure 1 Azithromycin attenuated viral-dependent weight loss. (A) Experiment time line. Seven-week-old C57BL/6J female mice were inoculated with Sendai virus 5,000 egg infectious dose 50% (SeV 5 K). Mice were treated daily with PBS or azithromycin day 0 (one hour after SeV inoculation)
through day 7. On days 8 and 21, bronchoalveolar lavage (BAL) fluid and lungs and were harvested. (B) Percentage of weight change from baseline
(day 0) in PBS (black square) versus azithromycin (black triangle) treated mice. Values are the mean ± SEM (n = 23 in each group). A significant decrease
between PBS and azithromycin treatment is indicated (*, p < 0.05). (C) Kaplan-Meier analysis of survival. No statistical difference between treatment
groups (n = 23 in each group) was determined by log-rank test.
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Lung sections were stained with hematoxylin and eosin
(H&E) and Periodic Acid-Schiff (PAS) [30,31]. Quantification of mucus producing cells was performed by counting the number of airway cells that stained with PAS
positive cells and using a PAS score as previously
described [30,36,37]. Peripheral blood leukocyte counts
were performed using an automated veterinary hematologic analyzer with a pre-programmed murine calibration
mode (Hemavet 950FS, Drew Scientific, Waterbury, CT)
as previously described [31].
PCR Quantification of Sendai virus

The quantity of Sendai virus-specific RNA was determined from whole lung using a TaqMan one-step fluorogenic RT-PCR reaction according to the manufacturer's
recommendation (Applied Biosystems, Foster City, CA)
[29,31]. Lung tissue was placed in RNA Later (Applied
Biosystems), homogenized with stainless steel beads for 3
min (Biospect Products Inc., Bartlesville, OK), and column purified with an RNeasy mini kit according to the
manufacturer's recommendations (Qiagen, Alencia, CA).
Duplicate serial 10-fold dilutions of total RNA from Sendai-infected lung tissue underwent one-step fluorogenic
RT-PCR for detection of Sendai virus nucleocapsid protein transcripts (upstream primer 5'-TCCACCCTGAGGAGCAGG-3'; downstream primer 5'-ACCCGGCCAT
CGTGAACT-3'; probe 5'-6FAM-TGGCAGCAAAGCAA
AGGGTCTGGA-TAMRA-30) and murine GAPDH specific RNA (proprietary primer/probe combination,
Applied Biosystems; #MM99999915G1) to construct
standard curves. Sendai values were calculated as the
mean of duplicate samples from reactions with a cycle
threshold between 20 and 25 and final results were normalized to GAPDH and reported as the Sendai/GAPDH
ratio.
Statistical analysis

Means from multiple groups (BAL cell counts and
inflammatory mediator concentrations on day 8) were
analyzed for statistical significance using a one-way analysis of variance (ANOVA) and post hoc comparison to
identify significant differences between specific groups.
An independent group's t-test was used to compare
means from two groups (BAL cell counts and inflammatory mediator concentrations on day 21). The MannWhitney test was used to compare the lung PAS scores
(an ordinal variable). The significance level for all tests
was 0.05. Data were analyzed using SPSS 15 software
(Chicago, IL).

Results
Azithromycin attenuated viral-dependent weight loss

To determine if azithromycin could confer anti-inflammatory properties in a mouse model of viral bronchioli-
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tis, we inoculated mice on day 0 with SeV (5,000 egg
infectious dose 50%, 5 K) and treated the mice daily with
azithromycin or PBS from day 0 to day 7 (Figure 1A).
Mice treated with azithromycin had attenuated weight
loss compared to PBS treated mice, with significant differences observed on days 3 through 9 post-inoculation
(Figure 1B). We noted a trend toward lower mortality in
the azithromycin treated mice (Figure 1C): 23/23 mice
survived in the azithromycin group versus 21/23 in the
control group (p = 0.12). To assess whether azithromycin
treatment would be beneficial using a higher infectious
dose, we performed an experiment using a lethal infectious dose of virus (50,000 egg infectious dose 50%, 50 K).
Treatment of this lethal infection with azithromycin did
not significantly alter weight loss, overall survival or delay
the time of death compared to treatment with PBS (N = 5
in each cohort). These results demonstrated that azithromycin treatment, in the 5 K infectious dose, attenuated
some clinical features of the severity of the acute viral
bronchiolitis. Therefore, we next sought to characterize
the impact of azithromycin treatment on lung inflammation.
Azithromycin attenuated viral-dependent airway
inflammation

To determine whether azithromycin treatment could
attenuate airway inflammation during the SeV 5 K infection, we examined the lungs from PBS and azithromycin
treated mice 8 days following viral inoculation. This time
point correlates to peak post-viral airway inflammation
[31]. Compared to naive mice, SeV inoculated mice
treated with PBS had an accumulation of immune cells
predominantly in the peribronchial space, in the airway
lumen, and to a lesser extent in the alveolar spaces. In
some airways we observed severe epithelial cell injury
with disruption of the epithelial layer as described previously (Figure 2, middle panels) [38]. Treatment with
azithromycin attenuated the accumulation of inflammatory cells in the lung tissue (Figure 2, right panels). To
quantify the accumulation of immune cells in the airways
we collected the BAL fluid. In agreement with the histologic appearance of the lung tissue, azithromycin treatment significantly attenuated the accumulation of total
BAL immune cells (Figure 3A). Analysis of the BAL leukocyte populations demonstrated that azithromycin
treatment significantly decreased the accumulation of
macrophages, lymphocytes and neutrophils, with the
largest fold-reduction in the number of neutrophils (Figure 3B-D). To exclude the possibility that azithromycin
treatment decreased accumulation of immune cells in the
airways by a systemic depletion of immune cells, we
quantified total and differential leukocytes in the peripheral blood at day 8 post-viral inoculation. We observed no
significant differences between PBS and azithromycin-
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Figure 2 Azithromycin attenuated viral-dependent airway inflammation. Mice were inoculated with SeV and treated as in Figure 1. Eight days
post-viral inoculation, lung sections were obtained from naive mice (Naive, left column); SeV infected mice treated with PBS (SeV + PBS, middle column), and SeV infected mice treated with azithromycin (SeV + Azithro, right column). Representative photomicrographs of hematoxylin and eosin
stained lung sections are shown (n = 11, Azithro; n = 12, PBS). Inflammatory cells within the airway are indicated (arrow). Bar = 50 μm (top) and 25 μm
(bottom).

treated cohorts, in terms of total leukocytes (mean cells/
μL ± SD, 4100 ± 1300 vs. 4000 ± 600 respectively; p =
0.81) or numbers of macrophages, lymphocytes or neutrophils (data not shown). Thus, azithromycin treatment
attenuated lung inflammation in this model of viral bronchiolitis.
Azithromycin attenuated viral-dependent airway
inflammation is associated with decreased concentrations
of BAL inflammatory mediators

Based on the observation that azithromycin treatment
decreased immune cell accumulation on day 8 post-inoculation, we proposed that azithromycin treatment would
also be associated with decreased concentration of BAL
inflammatory mediators. Compared to SeV inoculated
mice treated with PBS, treatment with azithromycin
attenuated the expression of multiple BAL chemokines
and growth factors (Figure 4A-D, column 2 versus 3).
Importantly, we observed a significant azithromycindependent decrease in G-CSF and decreased concentrations, albeit not statistically significant, of CCL2/JE,
CCL3/MIP-1α, CCL4/MIP-1β and CCL5/RANTES; all
these are proteins known to mediate viral immune
response (e.g., chemotaxis and activation of inflammatory cells at site of inflammation). In addition, azithromycin treatment resulted in trends toward lower
concentrations of multiple other inflammatory mediators

in the BAL (IL-1β, IL-5, IL-6, IL-9, IL-10, IL-12, GM-CSF
and IFN-γ), but had no effect on concentration of IL-17
and CXCL1/KC (data not shown). These data demonstrate that azithromycin moderated the viral-dependent
secretion of multiple BAL mediators, several of which are
critical for chemotaxis and activation of inflammatory
cells.
Azithromycin modulation of viral-dependent airway
inflammation is independent of Sendai viral load

To investigate whether azithromycin had an effect on SeV
burden in the lung tissue, we quantified SeV-specific
RNA at day 5 and 8 post-viral inoculation. These time
points were chosen based on our previous data that demonstrated peak viral load in the lungs occurred on day 5
post-inoculation, and virus clearance on day 8 post-inoculation [31]. There were no differences in SeV-specific
RNA between PBS or azithromycin treated mice suggesting azithromycin does not directly alter viral replication
or clearance (Figure 5). Thus, in this model of viral bronchiolitis, azithromycin anti-inflammatory properties are
independent of an anti-viral property.
Azithromycin treatment attenuated chronic viraldependent airway inflammation

As noted above, azithromycin treatment from day 0
through day 7 post-viral inoculation attenuated viral-
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Figure 3 Azithromycin attenuated viral-dependent accumulation of total cells, macrophages, lymphocytes and neutrophils in the BAL. BAL
from mice treated as in Figure 1 was analyzed for total and differential cell number eight days post-inoculation. Groups are labeled as in Figure 2A and
values are the mean ± SEM (n = 11, Azithro; n = 12, PBS) of total BAL cells (A), macrophages (B), lymphocytes (C) and neutrophils (D). A significant
decrease between PBS and azithromycin treatment is indicated (*, p < 0.05).
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Figure 4 Azithromycin attenuated viral-dependent airway inflammation is associated with decreased concentrations of BAL inflammatory
mediators. BAL from mice treated as in Figure 1 was analyzed for inflammatory mediators eight days post-inoculation. Concentrations of inflammatory mediators in the cell-free BAL supernatant were determined using a multiplex flow-cytometry based assay (Bio-Rad Laboratories). Groups are labeled as in Figure 2B and values are the mean ± SEM (n = 11, Azithro; n = 12, PBS) of G-CSF (A), CCL2/JE (B), CCL4/MIP-1β (C), CCL5/RANTES (D). A
significant decrease between PBS and azithromycin treatment is indicated (*, p < 0.05).

Beigelman et al. Respiratory Research 2010, 11:90
http://respiratory-research.com/content/11/1/90

Figure 5 Azithromycin attenuated viral-dependent airway inflammation is independent of Sendai virus load. Mice were inoculated with SeV and treated as in Figure 1. Five and eight days postinoculation, whole-lung RNA was analyzed for Sendai virus-specific
and GAPDH RNA by one-step fluorogenic reverse transcriptase-polymerase chain reaction (RT-PCR). The mean of duplicate measurements
of SeV-specific RNA was normalized to GAPDH and reported as the SeV
to GAPDH ratio. Values are the mean ± SEM (n = 6, day 5; n = 4, day 8).

dependent airway inflammation at day 8 (peak of inflammation). Next we investigated whether azithromycin
would also modify the chronic inflammatory phase of the
infection. On day 21 post-viral inoculation, the accumulation of total BAL immune cells was elevated compared
to naive mice. There were fewer total cells (although not
statistically significant) in the BAL of the azithromycin
treated cohort compared to those treated with PBS (Figure 6A). There was a trend toward fewer BAL neutrophils
in the azithromycin treated mice (Figure 6B). Moreover,
azithromycin treatment resulted in a significant decrease
in the BAL concentrations of G-CSF and CXCL1/KC
(Figure 6C-D), and in a trend toward a decreased concentration of CCL2/JE (data not shown). No statistical difference was noted between the azithromycin and PBS
treated mice in terms of the extent of mucous cell metaplasia (PAS score 1.1 vs. 1.0 respectively; p = 0.58). These
results demonstrated that azithromycin treatment altered
not only acute airway inflammation, but modified certain
key aspects of the chronic inflammatory phase of the
infection.

Discussion
This study demonstrated that azithromycin possessed
beneficial anti-inflammatory properties in a mouse
model of paramyxoviral bronchiolitis. Azithromycin
treatment improved the course of acute disease, evidenced by decreased weight loss and attenuated accumu-
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lation of BAL inflammatory cells and chemokines.
Although not statistically significant, we noted a trend
toward lower mortality in the azithromycin treated mice.
We also observed that early azithromycin treatment was
associated with modulation of certain features of the
chronic post-viral inflammatory phase. To the best of our
knowledge, this is the first study to demonstrate the beneficial effects of azithromycin in a mouse model of viral
bronchiolitis and suggests this drug may also have beneficial effects in human bronchiolitis.
Our results are in agreement with a previous study by
Sato and colleagues, who investigated the effect of erythromycin treatment using an in vivo model of influenza
pneumonia [39]. That study showed that erythromycin
treatment in mice resulted in improved survival,
decreased weight loss, and attenuated airway inflammation. Our results extend those findings by demonstrating
that a clinically better tolerated macrolide displayed antiinflammatory properties in a different viral infection
model (i.e., a parainfluenza viral bronchiolitis vs. influenza pneumonia). In addition, we demonstrated that
treatment of the acute inflammation is associated with
attenuation of the chronic post-viral inflammatory phase.
Our results revealed that azithromycin had no effect on
SeV viral kinetics in the lung tissue at day 5 and 8 postviral inoculation, time points that corresponded to the
peak of viral load in the lungs and virus clearance respectively [31]. Accordingly, in this case we conclude that
azithromycin has anti-inflammatory, but no direct in vivo
anti-viral properties. This observation agrees with the
previously mentioned report, in which erythromycin
treatment did not alter influenza viral kinetics [39].
Although weight loss is attenuated and viral clearance is
not compromised by treatment with azithromycin, it
remains unclear how azithromycin or other macrolides
would alter additional clinical outcomes of a human viral
infection such as nasal congestion, nasal discharge, and
cough as we have not developed techniques to quantitate
these in the mouse. We do note that a recent study found
that macrolide antibiotics inhibited RSV infection in isolated human tracheal epithelial cells [40]. These apparently conflicting results could be related to differences
between in vivo and in vitro viral infection models, use of
different paramyxoviruses, or to different dosing regimens and pharmacologic properties of the drugs.
During the peak inflammatory response, azithromycin
treatment attenuated cellular influx in the lung tissue and
BAL. Decreased cellular influx in site of inflammation is
consistent with previous reports in other inflammatory
models in which macrolides attenuated neutrophilic
inflammation induced by inhaled LPS [41,42] or intratracheal P. aeruginosa infection [43]. The effect of azithromycin, in our viral bronchiolitis model, does not appear
to be neutrophil-specific since the accumulation of mac-
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Figure 6 Azithromycin treatment attenuated chronic viral-dependent airway inflammation. Mice were inoculated with SeV and treated as in
Figure 1. Twenty-one days post-inoculation, lung sections and BAL fluid were harvested. Values are the mean ± SEM (n = 10, Azithro; n = 8, PBS) of
total BAL cells (A), macrophages, lymphocytes and neutrophils in the BAL (B), and concentrations of the chemokines: G-CSF (C) and CCL1/KC (D). A
significant decrease between PBS and azithromycin treated mice is indicated (*, p < 0.05).

rophages and lymphocytes were also attenuated. In previous work, we demonstrated that azithromycin had the
most profound effect on eosinophils in an in vivo allergic
model of airway inflammation [30]. Taken together, these
observations suggest that macrolides possess broad antiinflammatory properties that can attenuate the accumulation of multiple cell types in various airway inflammatory models.
One limitation of this study is the initiation of azithromycin treatment on the day of infection. Another limitation is that we did not test for a beneficial treatment
effect of azithromycin on other respiratory viruses, such
as RSV. RSV is a human pathogen and in our experience
RSV infection of mice results in pneumonia rather then
bronchiolitis. We have found that SeV replicates at high
efficiency in the mouse lung and results in acute inflammation of the small airways (i.e., bronchiolitis) that better
mimics human bronchiolitis. Since we have not tested for
a beneficial treatment effect of azithromycin on RSV
infection it is difficult to compare our results to previous
studies that modulated the host immune response by
blocking the CX3C chemokine activity of the G protein of
RSV [44-46]. Future studies will be required to determine
if different treatment regimens, such as initiation of treatment a few days after inoculation or alternate dosing regimens would result in a similar beneficial treatment effect
on SeV as well as other respiratory viruses.
Although the precise biochemical mechanisms responsible for the anti-inflammatory effects of macrolides are
not defined, this family of drugs can inhibit multiple cellular processes involved in an inflammatory response. For

example, macrolides have been shown to inhibit neutrophil chemotaxis, leukocyte-epithelial cell adhesion,
cytokine secretion and cytokine-dependent intracellular
signaling [43,47]. In this regard, macrolides block NF-κB
and AP-1 dependent gene transcription of inflammatory
mediators [42,48,49]. Thus, additional studies will be
required to further define the precise cellular mechanisms responsible for the anti-inflammatory effects of
azithromycin and to determine the optimal dosing regimens required to attenuate both the acute and chronic
post-viral inflammatory phenotypes.
Previous clinical studies have shown that macrolides
are beneficial in the treatment of inflammatory airway
diseases such as diffuse panbronchiolitis [13], cystic
fibrosis [14], and asthma [15-25]. Two previous studies
investigated the effects of macrolide treatment in children hospitalized with RSV bronchiolitis [26,27]. Tahan
et al. [27] revealed that a 21 day course of clarithromycin
treatment reduced length of hospital stay, the duration of
additional treatments (supplemental oxygen, intravenous
fluids and bronchodilators) and the day 21 concentrations of IL-4, IL-8 and eotaxin in the serum. However,
this study was limited by a relatively small sample size (n
= 21). In a recent larger study, Kneyber et al. found that
azithromycin treatment did not improve the early disease
course in infants hospitalized with RSV bronchiolitis
[26]. This study, although important, had two main limitations that may have obscured any potential benefits of
the macrolide. First, the researchers designed an equivalence study based on the assumption that a difference less
than ± 49.4 hours (approximately ± 2 days) in length of
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hospitalization would be considered as equivalence (i.e.,
no benefit for treatment). Therefore, this study was not
powered to detect smaller differences in length of hospitalization. Second, the researchers recruited only 71% of
the required study population that was determined based
on their power analysis. This early termination of the trial
prevents definitive conclusions.
The current study highlights the importance of measuring macrolide-dependent effects during the early
phase of the viral infection as well as the late phase. In
addition we have identified certain growth factors and
chemokines (i.e., G-CSF, CCL2, CCL4, CCL5, and
CXCL1) that could be tracked to establish a beneficial
treatment effect. Accordingly, when planning a human
study we feel early and long-term follow-up of clinical
and biochemical endpoints should be included in the
study design.
Our study revealed that treatment of mouse SeV bronchiolitis with azithromycin during the acute infection
would attenuate acute and chronic airway inflammation,
and also decrease the chronic post-viral pathologic
abnormalities. However, we do not recommend the offlabel use of azithromycin during RSV infection until
additional prospective randomized clinical trials support
its use since excessive use of macrolides has correlated
with increased prevalence of macrolide-resistant organisms such as Streptococcus pneumonia [50].

Conclusions
Our results extend previous findings obtained in different
in vivo models by demonstrating that azithromycin possessed anti-inflammatory properties in an in vivo model
of viral bronchiolitis. We found that early treatment during viral infection is associated with attenuation of acute
and chronic airway inflammation. Azithromycin treatment improved the course of acute disease, evidenced by
decreased weight loss and attenuated accumulation of
BAL inflammatory cells and chemokines. Our data
revealed that early azithromycin treatment also modulates the chronic post-viral inflammatory phase. These
results support the rationale for future prospective randomized clinical trials that will evaluate the effects of
macrolides on acute viral bronchiolitis and their longterm consequences.
Abbreviation list
ANOVA: Analysis of Variance; BAL: Bronchoalveolar
Lavage; GAPDH: Glyceraldehyde 3-Phosphate Dehydrogenase; H&E: Hematoxylin and Eosin; PAS: Periodic
Acid-Schiff; RSV: Respiratory Syncytial Virus; SeV: Sendai Virus.

Page 10 of 11

Competing interests disclosures
The authors declare that they have no competing interests.
Authors' contributions
AB: Designed the study, performed the experiments, performed statistical analysis, interpreted the data, and wrote the manuscript. CLM, SG: Performed the
experiments, participated in revision of the manuscript, provided final approval
of the manuscript. CLC, SLB: Participated in study design, participated in revision of the manuscript, provided final approval of the manuscript. MJW:
Designed the study, performed statistical analysis, interpreted the data, and
wrote the manuscript. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by the National Institutes of Health [NIH R01HL083894].
Author Details
1Division of Allergy, Immunology & Pulmonary Medicine, Department of
Pediatrics, Washington University School of Medicine, St. Louis, MO; USA and
2Division of Pulmonary and Critical Care Medicine, Department of Internal
Medicine, Washington University School of Medicine, St. Louis, MO; USA
Received: 2 March 2010 Accepted: 30 June 2010
Published: 30 June 2010
©
This
Respiratory
2010
is
article
an
Beigelman
Open
is
Research
available
Access
et2010,
al;from:
article
licensee
11:90
http://respiratory-research.com/content/11/1/90
distributed
BioMed Central
under the
Ltd.terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References
1. Glezen WP, Taber LH, Frank AL, Kasel JA: Risk of primary infection and
reinfection with respiratory syncytial virus. Am J Dis Child 1986,
140(6):543-546.
2. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR: Rates of
hospitalization for respiratory syncytial virus infection among children
in medicaid. J Pediatr 2000, 137(6):865-870.
3. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ:
Bronchiolitis-associated hospitalizations among US children, 19801996. JAMA 1999, 282(15):1440-1446.
4. Leader S, Kohlhase K: Respiratory syncytial virus-coded pediatric
hospitalizations, 1997 to 1999. Pediatr Infect Dis J 2002, 21(7):629-632.
5. Sigurs N: Epidemiologic and clinical evidence of a respiratory syncytial
virus-reactive airway disease link. Am J Respir Crit Care Med 2001, 163(3
Pt 2):S2-6.
6. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B: Respiratory syncytial
virus bronchiolitis in infancy is an important risk factor for asthma and
allergy at age 7. Am J Respir Crit Care Med 2000, 161(5):1501-1507.
7. Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S,
Sigurbergsson F, Kjellman B: Severe respiratory syncytial virus
bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir
Crit Care Med 2005, 171(2):137-141.
8. Castro M, Schweiger T, Yin-Declue H, Ramkumar TP, Christie C, Zheng J,
Cohen R, Schechtman KB, Strunk R, Bacharier LB: Cytokine response after
severe respiratory syncytial virus bronchiolitis in early life. J Allergy Clin
Immunol 2008, 122(4):726-733.
9. Carroll KN, Wu P, Gebretsadik T, Griffin MR, Dupont WD, Mitchel EF, Hartert
TV: The severity-dependent relationship of infant bronchiolitis on the
risk and morbidity of early childhood asthma. J Allergy Clin Immunol
2009, 123(5):1055-1061.
10. Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB: Impact of
respiratory virus infections on persons with chronic underlying
conditions. JAMA 2000, 283(4):499-505.
11. Diagnosis and management of bronchiolitis. Pediatrics 2006,
118(4):1774-1793.
12. Shinkai M, Rubin BK: Macrolides and airway inflammation in children.
Paediatr Respir Rev 2005, 6(3):227-235.
13. Koyama H, Geddes DM: Erythromycin and diffuse panbronchiolitis.
Thorax 1997, 52(10):915-918.
14. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M: Long term azithromycin in
children with cystic fibrosis: a randomised, placebo-controlled
crossover trial. Lancet 2002, 360(9338):978-984.

Beigelman et al. Respiratory Research 2010, 11:90
http://respiratory-research.com/content/11/1/90

15. Miyatake H, Taki F, Taniguchi H, Suzuki R, Takagi K, Satake T: Erythromycin
reduces the severity of bronchial hyperresponsiveness in asthma.
Chest 1991, 99(3):670-673.
16. Shimizu T, Kato M, Mochizuki H, Tokuyama K, Morikawa A, Kuroume T:
Roxithromycin reduces the degree of bronchial hyperresponsiveness
in children with asthma. Chest 1994, 106(2):458-461.
17. Kamoi H, Kurihara N, Fujiwara H, Hirata K, Takeda T: The macrolide
antibacterial roxithromycin reduces bronchial hyperresponsiveness
and superoxide anion production by polymorphonuclear leukocytes
in patients with asthma. J Asthma 1995, 32(3):191-197.
18. Shimizu T, Kato M, Mochizuki H, Takei K, Maeda S, Tokuyama K, Morikawa
A: Roxithromycin attenuates acid-induced cough and water-induced
bronchoconstriction in children with asthma. J Asthma 1997,
34(3):211-217.
19. Amayasu H, Yoshida S, Ebana S, Yamamoto Y, Nishikawa T, Shoji T,
Nakagawa H, Hasegawa H, Nakabayashi M, Ishizaki Y: Clarithromycin
suppresses bronchial hyperresponsiveness associated with
eosinophilic inflammation in patients with asthma. Ann Allergy Asthma
Immunol 2000, 84(6):594-598.
20. Black PN, Blasi F, Jenkins CR, Scicchitano R, Mills GD, Rubinfeld AR, Ruffin
RE, Mullins PR, Dangain J, Cooper BC, David DB, Allegra L: Trial of
roxithromycin in subjects with asthma and serological evidence of
infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 2001,
164(4):536-541.
21. Ekici A, Ekici M, Erdemoglu AK: Effect of azithromycin on the severity of
bronchial hyperresponsiveness in patients with mild asthma. J Asthma
2002, 39(2):181-185.
22. Kraft M, Cassell GH, Pak J, Martin RJ: Mycoplasma pneumoniae and
Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest
2002, 121(6):1782-1788.
23. Kostadima E, Tsiodras S, Alexopoulos EI, Kaditis AG, Mavrou I, Georgatou N,
Papamichalopoulos A: Clarithromycin reduces the severity of bronchial
hyperresponsiveness in patients with asthma. Eur Respir J 2004,
23(5):714-717.
24. Johnston SL, Blasi F, Black PN, Martin RJ, Farrell DJ, Nieman RB: The effect
of telithromycin in acute exacerbations of asthma. N Engl J Med 2006,
354(15):1589-1600.
25. Piacentini GL, Peroni DG, Bodini A, Pigozzi R, Costella S, Loiacono A, Boner
AL: Azithromycin reduces bronchial hyperresponsiveness and
neutrophilic airway inflammation in asthmatic children: a preliminary
report. Allergy Asthma Proc 2007, 28(2):194-198.
26. Kneyber MC, van Woensel JB, Uijtendaal E, Uiterwaal CS, Kimpen JL:
Azithromycin does not improve disease course in hospitalized infants
with respiratory syncytial virus (RSV) lower respiratory tract disease: a
randomized equivalence trial. Pediatr Pulmonol 2008, 43(2):142-149.
27. Tahan F, Ozcan A, Koc N: Clarithromycin in the treatment of RSV
bronchiolitis: a double-blind, randomised, placebo-controlled trial. Eur
Respir J 2007, 29(1):91-97.
28. Kim EY, Battaile JT, Patel AC, You Y, Agapov E, Grayson MH, Benoit LA,
Byers DE, Alevy Y, Tucker J, Swanson S, Tidwell R, Tyner JW, Morton JD,
Castro M, Polineni D, Patterson GA, Schwendener RA, Allard JD, Peltz G,
Holtzman MJ: Persistent activation of an innate immune response
translates respiratory viral infection into chronic lung disease. Nat Med
2008, 14(6):633-640.
29. Walter MJ, Morton JD, Kajiwara N, Agapov E, Holtzman MJ: Viral induction
of a chronic asthma phenotype and genetic segregation from the
acute response. J Clin Invest 2002, 110(2):165-175.
30. Beigelman A, Gunsten S, Mikols CL, Vidavsky I, Cannon CL, Brody SL,
Walter MJ: Azithromycin Attenuates Airway Inflammation in a
Noninfectious Mouse Model of Allergic Asthma. Chest 2009,
136(2):498-506.
31. Gunsten S, Mikols CL, Grayson MH, Schwendener RA, Agapov E, Tidwell
RM, Cannon CL, Brody SL, Walter MJ: IL-12 p80-dependent macrophage
recruitment primes the host for increased survival following a lethal
respiratory viral infection. Immunology 2009, 126(4):500-513.
32. Mikols CL, Yan L, Norris JY, Russell TD, Khalifah AP, Hachem RR, Chakinala
MM, Yusen RD, Castro M, Kuo E, Patterson GA, Mohanakumar T, Trulock EP,
Walter MJ: IL-12 p80 is an innate epithelial cell effector that mediates
chronic allograft dysfunction. Am J Respir Crit Care Med 2006,
174(4):461-470.
33. Russell TD, Yan Q, Fan G, Khalifah AP, Bishop DK, Brody SL, Walter MJ: IL-12
p40 homodimer-dependent macrophage chemotaxis and respiratory

Page 11 of 11

34.

35.

36.

37.

38.

39.

40.

41.

42.

43.

44.

45.

46.

47.

48.

49.
50.

viral inflammation are mediated through IL-12 receptor beta 1. J
Immunol 2003, 171(12):6866-6874.
Hoffmann N, Lee B, Hentzer M, Rasmussen TB, Song Z, Johansen HK,
Givskov M, Hoiby N: Azithromycin blocks quorum sensing and alginate
polymer formation and increases the sensitivity to serum and
stationary-growth-phase killing of Pseudomonas aeruginosa and
attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice.
Antimicrob Agents Chemother 2007, 51(10):3677-3687.
Conte JE Jr, Golden J, Duncan S, McKenna E, Lin E, Zurlinden E: Singledose intrapulmonary pharmacokinetics of azithromycin,
clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects.
Antimicrob Agents Chemother 1996, 40(7):1617-1622.
Bao Z, Lim S, Liao W, Lin Y, Thiemermann C, Leung BP, Wong WS:
Glycogen synthase kinase-3beta inhibition attenuates asthma in mice.
Am J Respir Crit Care Med 2007, 176(5):431-438.
Duan W, Chan JH, Wong CH, Leung BP, Wong WS: Anti-inflammatory
effects of mitogen-activated protein kinase kinase inhibitor U0126 in
an asthma mouse model. J Immunol 2004, 172(11):7053-7059.
Look DC, Walter MJ, Williamson MR, Pang L, You Y, Sreshta JN, Johnson JE,
Zander DS, Brody SL: Effects of paramyxoviral infection on airway
epithelial cell Foxj1 expression, ciliogenesis, and mucociliary function.
Am J Pathol 2001, 159(6):2055-2069.
Sato K, Suga M, Akaike T, Fujii S, Muranaka H, Doi T, Maeda H, Ando M:
Therapeutic effect of erythromycin on influenza virus-induced lung
injury in mice. Am J Respir Crit Care Med 1998, 157(3 Pt 1):853-857.
Asada M, Yoshida M, Suzuki T, Hatachi Y, Sasaki T, Yasuda H, Nakayama K,
Nishimura H, Nagatomi R, Kubo H, Yamaya M: Macrolide antibiotics
inhibit respiratory syncytial virus infection in human airway epithelial
cells. Antiviral Res 2009, 83(2):191-200.
Ivetic Tkalcevic V, Bosnjak B, Hrvacic B, Bosnar M, Marjanovic N, Ferencic Z,
Situm K, Culic O, Parnham MJ, Erakovic V: Anti-inflammatory activity of
azithromycin attenuates the effects of lipopolysaccharide
administration in mice. Eur J Pharmacol 2006, 539(1-2):131-138.
Leiva M, Ruiz-Bravo A, Jimenez-Valera M: Effects of telithromycin in in
vitro and in vivo models of lipopolysaccharide-induced airway
inflammation. Chest 2008, 134(1):20-29.
Tsai WC, Rodriguez ML, Young KS, Deng JC, Thannickal VJ, Tateda K,
Hershenson MB, Standiford TJ: Azithromycin blocks neutrophil
recruitment in Pseudomonas endobronchial infection. Am J Respir Crit
Care Med 2004, 170(12):1331-1339.
Harcourt JL, Karron RA, Tripp RA: Anti-G protein antibody responses to
respiratory syncytial virus infection or vaccination are associated with
inhibition of G protein CX3C-CX3CR1 binding and leukocyte
chemotaxis. J Infect Dis 2004, 190(11):1936-1940.
Zhang W, Choi Y, Haynes LM, Harcourt JL, Anderson LJ, Jones LP, Tripp RA:
Vaccination to induce antibodies blocking the CX3C-CX3CR1
interaction of respiratory syncytial virus G protein reduces pulmonary
inflammation and virus replication in mice. J Virol 84(2):1148-1157.
Haynes LM, Caidi H, Radu GU, Miao C, Harcourt JL, Tripp RA, Anderson LJ:
Therapeutic monoclonal antibody treatment targeting respiratory
syncytial virus (RSV) G protein mediates viral clearance and reduces
the pathogenesis of RSV infection in BALB/c mice. J Infect Dis 2009,
200(3):439-447.
Kawasaki S, Takizawa H, Ohtoshi T, Takeuchi N, Kohyama T, Nakamura H,
Kasama T, Kobayashi K, Nakahara K, Morita Y, Yamamoto K: Roxithromycin
inhibits cytokine production by and neutrophil attachment to human
bronchial epithelial cells in vitro. Antimicrob Agents Chemother 1998,
42(6):1499-1502.
Adachi T, Motojima S, Hirata A, Fukuda T, Kihara N, Kosaku A, Ohtake H,
Makino S: Eosinophil apoptosis caused by theophylline,
glucocorticoids, and macrolides after stimulation with IL-5. J Allergy
Clin Immunol 1996, 98(6 Pt 2):S207-215.
Hatipoglu U, Rubinstein I: Low-dose, long-term macrolide therapy in
asthma: An overview. Clin Mol Allergy 2004, 2(1):4.
Jenkins SG, Farrell DJ: Increase in pneumococcus macrolide resistance,
United States. Emerg Infect Dis 2009, 15(8):1260-1264.

doi: 10.1186/1465-9921-11-90
Cite this article as: Beigelman et al., Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis Respiratory Research 2010,
11:90

